Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market
  • Trading will begin on September 29, 2021, under the ticker symbol IONM
  • The company believes the listing will benefit its liquidity and appeal for potential future acquisitions
  • Assure Holdings provides a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries
  • Assure Holdings (IOM) is unchanged trading at $9.30 per share

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.

Trading will begin on September 29, 2021, under the ticker symbol IONM.

The company’s stock will continue trading on the OTCQB Venture Market until trading commences on the NASDAQ.

It will retain its listing on the TSXV.

John A. Farlinger, Assure’s Executive Chairman and CEO, stated,

“Our listing on NASDAQ represents a significant milestone for Assure. We believe that a NASDAQ listing increases Assure’s visibility in the industry. In addition, the listing is expected to provide increased liquidity to our investors, improve our access to capital and enhance the value of our common stock for future M&A transactions.”

Assure Holdings provides a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.

Assure Holdings (IOM) is unchanged trading at $9.30 per share as of 11:35 am ET.

More From The Market Herald

" Andlauer Healthcare Group (TSX:AND) completes $169M bought deal offering

Andlauer Healthcare Group Inc. (AND) and Andlauer Management Group Inc. completed a bought deal offering of 3.5 million subordinate voting shares (SVSs).

" Avricore (TSXV:AVCR) expands HealthTab to select Shoppers Drug Mart locations in BC

Avricore Health (AVCR) has expanded its patient testing with the HealthTab platform in select Shoppers Drug Mart pharmacies in BC.

" Clearmind (CSE:CMND) signs development and supply agreement with Aragen Life Sciences

Clearmind Medicine (CMND) will work with Aragen Life Sciences to produce its innovative molecule, 5-Methoxy-2-aminoindane (MEAI).

" Aptose (TSX:APS) expands senior leadership team

Aptose Biosciences (TSX: APS) has appointed two key members to its management team to support its finance and operations functions.